Cell Therapy for Urinary Stress Incontinence is under clinical development by MUVON Therapeutics and currently in Phase II for Stress Urinary Incontinence. According to GlobalData, Phase II drugs for Stress Urinary Incontinence does not have sufficient historical data to build an indication benchmark PTSR for Phase II. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the Cell Therapy for Urinary Stress Incontinence LoA Report. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Cell Therapy for Urinary Stress Incontinence overview
Cell therapy is under development for the treatment of urinary stress incontinence. It is administered through parenteral route. The drug candidate comprises of autologous muscle precursor cells (MPCs) in a combination with neuro-muscular electromagnetic stimulation (NMES).
MUVON Therapeutics overview
MUVON Therapeutics is a biotechnology which focuses on the development and commercialization of an autologous cell therapy for the treatment of stress urinary incontinence. The company is headquartered in Zurich, Switzerland.
For a complete picture of Cell Therapy for Urinary Stress Incontinence’s drug-specific PTSR and LoA scores, buy the report here.